NCT07743996 Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study
| NCT ID | NCT07743996 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boehringer Ingelheim |
| Condition | Idiopathic Pulmonary Fibrosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-08-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.
Eligibility Criteria
Inclusion Criteria: 1. Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks 2. Patients capable of responding to a self-administered questionnaire Exclusion Criteria: 1. Patients treated with nerandomilast (including clinical trials) 2. Patients with PPF treated with pirfenidone 3. Patients currently hospitalized 4. Patients with malignant tumors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07743996 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Idiopathic Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07743996 currently recruiting?
Yes, NCT07743996 is actively recruiting participants. Contact the research team at clintriage.rdg@boehringer-ingelheim.com for enrollment information.
Where is the NCT07743996 trial being conducted?
This trial is being conducted at Tokyo, Japan.
Who is sponsoring the NCT07743996 clinical trial?
NCT07743996 is sponsored by Boehringer Ingelheim. The trial plans to enroll 100 participants.